Yıl: 2008 Cilt: 38 Sayı: 3 Sayfa Aralığı: 257 - 262 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Antimicrobial susceptibility of Brucella melitensis isolates from blood samples

Öz:
Amaç: Bruselloz tüm dünyada yaygın olarak görülen ve ülkemizde kırsal alanlar başta olmak üzere önemli bir sağlık sorunu oluşturan zoonotik bir hastalıktır. Bu çalışmada, kan örneklerinden izole edilen Brucella cinsi bakterilerde tür/biyotip tayini yapılması ve bu suşların antimikrobiyal duyarlılıklarının belirlenmesi amaçlanmıştır. Yöntem ve Gereç: Çalışmaya Kırıkkale ilinde kan kültürlerinden izole edilmiş 46 Brucella suşu alınmıştır. ‹zolatların identifikasyon ve tür/biyotip tayininde konvansiyonel yöntemler kullanılmıştır. Tetrasiklin, streptomisin, rifampisin, siproşoksasin ve azitromisin için minimal inhibitör konsantrasyon (M‹K) değerlerinin belirlenmesinde E-test yöntemi kullanılmıştır. Bulgular: Tüm izolatlar B. melitensis (45’i biyotip-3) olarak belirlenmiştir. Antibiyotik duyarlılık sonuçlarına bakıldığında, izolatların tümü tetrasiklin, streptomisin, siproşoksasin ve azitromisin’e duyarlı bulunmuştur. Kırkdört suş rifampine duyarlı, iki suş ise orta duyarlı olarak saptanmıştır. Tetrasiklin, streptomisin, rifampin, siproşoksasin ve azitromisin için M‹K90 değerleri sırasıyla 0,25 mg/l, 0,50 mg/l, 1,0 mg/l, 0,25 mg/l ve 1,0 mg/l olarak değerlendirilmiştir. Sonuç: Son yıllarda, Brucella suşlarının identifikasyon ve antimikrobiyal duyarlılıklarının belirlenmesi üzerine büyük bir ilgi artışı vardır. Antibiyotik duyarlılık sonuçları Brucella suşlarında kullanılmakta olan konvansiyonel ilaçlara karşı in vitro direnç olmadığını göstermektedir. Bu çalışmadan elde edilen bulgular, Türkiye’de bu konuda yapılan benzer çalışmalar ve dünya verileri eşliğinde gözden geçirilmiştir.
Anahtar Kelime: Mikrobiyal duyarlılık testleri Siprofloksazin Brucella melitensis Azitromisin Rifampin

Konular: Cerrahi

Kan örneklerinden elde edilen Brucella melitensis suşlarının antimikrobiyal duyarlılık sonuçları

Öz:
Aim: Brucellosis is a worldwide zoonotic disease that remains an important public health problem in rural Turkey. The aim of the present study was to identify Brucella species and biotypes, and to assess the antimicrobial susceptibility of isolates from blood samples. Materials and Methods: The study included 46 Brucella isolates from the K›r›kkale region of central Anatolia. The identification and biotyping of the isolates were based on conventional methods. The minimal inhibitory concentration (MIC) values of tetracycline, rifampin, streptomycin, ciprofloxacin, and azithromycin were determined using the E test method. Results: All isolates were identified as B. melitensis (45 isolates, biotype-3) and were sensitive to tetracycline, streptomycin, ciprofloxacin, and azithromycin. In all, 2 isolates showed intermediate sensitivity to rifampin, whereas the others were sensitive. MIC90 values of tetracycline, streptomycin, rifampin, ciprofloxacin, and azithromycin were 0.25 mg/l, 0.50 mg/l, 1.0 mg/l, 0.25 mg/l, and 1.0 mg/l, respectively. Conclusions: In recent years there has been tremendous interest in the identification of Brucella strains and their antimicrobial susceptibility. According to antimicrobial susceptibility test results, none of the isolates in the K›r›kkale region of Turkey were resistant to the currently recommended antibiotics. The present study’s findings were discussed along with a brief review of similar studies from Turkey.
Anahtar Kelime: Brucella melitensis Azithromycin Rifampin Microbial Sensitivity Tests Ciprofloxacin

Konular: Cerrahi
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Young EJ. Brucella species. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 6th ed. Philadelphia: Churchill Livingstone; 2005. p.2669-74.
  • 2. Celik I, Akbulut HH. Lymphocyte subpopulations in patients with acute brucellosis. Turk J Med Sci 2005; 35: 237-41.
  • 3. Navarro-Martinez A, Solera J, Corredoira J, Beato JL, Martinez- Alfaro E, Atienzar M et al. Epididymoorchitis due to Brucella mellitensis: a retrospective study of 59 patients. Clin Infect Dis 2001; 33: 2017-22.
  • 4. Shapiro DS, Wong JN. Brucella. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, editors. Manual of Clinical Microbiology. 7th ed. Washington DC: ASM Press; 1999. p. 625-31.
  • 5. Ayaslioglu E, Tekeli E, Birengel S. Significant elevation of serum soluble CD14 levels in patients with brucellosis. Jpn J Infect Dis 2005; 58: 11-4.
  • 6. Akova M, Gur D, Livermore DM, Kocagoz T, Akalin HE. In vitro activities of antibiotics alone and in combination against Brucella melitensis at neutral and acidic pHs. Antimicrob Agents Chemother 1999; 43: 1298-1300.
  • 7. Solera J, Martinez-Alfaro E, Espinosa A. Recognition and optimum treatment of brucellosis. Drugs 1997; 53: 245-56.
  • 8. Corbel MJ. Microbiological aspects. In: Madkour MM, editor. Madkour’s Brucellosis. 2nd ed. Berlin Heidelberg New York: Springer-Verlag; 2001. p.51-64.
  • 9. Kose S, Kilic S, Ozbel Y. Identification of Brucella species isolated from proven brucellosis patients in Izmir, Turkey. J Basic Microbiol 2005; 45: 323-7.
  • 10. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing, 15th Informational Supplement. CLSI Document M 100-S15, Wayne, PA: USA, 2005.
  • 11. Bodur H, Balaban N, Aksaray S, Yetener V, Akinci E, Colpan A et al. Biotypes and antimicrobial susceptibilities of Brucella isolates. Scand J Infect Dis 2003; 35: 337-8.
  • 12. Baykam N, Esener H, Ergonul O, Eren S, Celikbas AK, Dokuzoguz B. In vitro antimicrobial susceptibility of Brucella species. Int J Antimicrob Agents 2004; 23: 405-7.
  • 13. Sengoz G, Yasar KK, Kutlu SB, Durdu YB, Ozdemir R, Nazlican O. E-test susceptibility results of Brucella strains for streptomycin, rifampicin, ciprofloxacin and tetracycline. Mikrobiyol Bul 2006; 40: 265-8.
  • 14. Yamazhan T, Aydemir S, Tunger A, Serter D, Gokengin D. In vitro activities of various antimicrobials against Brucella melitensis strains in the Aegean region in Turkey. Med Princ Pract 2005;14: 413-6.
  • 15. Turkmani A, Ioannidis A, Christidou A, Psaroulaki A, Loukaides F, Tselentis Y. In vitro susceptibilities of Brucella melitensis isolates to eleven antibiotics. Ann Clin Microbiol Antimicrob 2006; 5:24.
  • 16. Madkour MM. Treatment. In: Madkour MM, editor. Madkour’s Brucellosis. 2nd edn. Berlin Heidelberg New York: Springer- Verlag; 2001. p.241-61.
  • 17. Gur D, Kocagoz S, Akova M, Unal S: Comparison of E test to microdilution for determining in vitro activities of antibiotics against Brucella melitensis. Antimicrob Agents Chemother 1999;43: 2337.
  • 18. Hall WH. Modern chemotherapy for brucellosis in humans. Rev Infect Dis 1990; 12: 1060-99.
  • 19. Pappas G, Solera J, Akritidis N, Tsianos E. New approaches to the antibiotic treatment of brucellosis. Int J Antimicrob Agents 2005;26: 101-5.
  • 20. Ariza J, Gudiol F, Pallares R, Viladrich PF, Rufi G, Corredoira J, Miravitlles MR. Treatment of human brucellosis with doxycycline plus rifampin or doxycycline plus streptomycin. A randomized, double-blind study. Ann Intern Med 1992; 117: 25-30.
  • 21. Garcia-Rodriguez JA, Garcia Sanchez JE, Trujillano I, Garcia Sanchez E, Garcia Garcia MI, Fresnadillo MJ. Susceptibilities of Brucella melitensis isolates to clinafloxacin and four other new fluoroquinolones. Antimicrob Agents Chemother 1995; 39:1194-5.
  • 22. Doganay M, Aygen B. Use of ciprofloxacin in the treatment of brucellosis. Eur J Clin Microbiol Infect Dis 1992; 11: 74-5.
  • 23. Lang R, Raz R, Sacks T, Shapiro M. Failure of prolonged treatment with ciprofloxacin in acute infections due to Brucella melitensis. J Antimicrob Chemother 1990; 26: 841-6.
  • 24. Agalar C, Usubutun S, Turkyilmaz R. Ciprofloxacin and rifampicin versus doxycycline and rifampicin in the treatment of brucellosis. Eur J Clin Microbiol Infect Dis 1999; 18: 535-8.
  • 25. Akova M, Uzun O, Akalin E, Hayran M, Unal S, Gur D. Quinolones in treatment of human brucellosis: comparative trial of ofloxacinrifampin versus doxycycline-rifampin. Antimicrob Agents Chemother 1993; 37: 1831-1834.
  • 26. Saltoglu N, Tasova Y, Inal AS, Seki T, Aksu HS. Efficacy of rifampicin plus doxycycline versus rifampicin plus quinolone in the treatment of brucellosis. Saudi Med J 2002; 23: 921-924.
  • 27. Kalo T, Novi S, Nushi A, Dedja S. Ciprofloxacin plus doxycycline versus rifampicin plus doxycycline in the treatment of acute brucellosis.Med Mal Infect 1996; 26: 587-9.
  • 28. Karabay O, Sencan I, Kayas D, Sahin I. Ofloxacin plus rifampicin versus doxycycline plus rifampicin in the treatment of brucellosis: a randomized clinical trial. BMC Infect Dis 2004; 4: 18.
  • 29. Solera J, Beato JL, Martinez-Alfaro E, Segura JC, de Tomas E; Grupo de Estudio de Castilla la Mancha de Enfermedades Infecciosas Group. Azithromycin and gentamicin therapy for the treatment of humans with brucellosis. Clin Infect Dis 2001; 3:506-9.
  • 30. Lopez-Merino A, Contreras-Rodriguez A, Migranas-Ortiz R, Orrantia-Gradin R, Hernandez-Oliva GM, Gutierrez-Rubio AT et al. Susceptibility of Mexican Brucella isolates to moxifloxacin, ciprofloxacin and other antimicrobials used in the treatment of human brucellosis. Scand J Infect Dis 2004; 36: 636-8.
APA AYAŞLIOĞLU AÇIKGÖZ E, KILIÇ S, AYDIN K, KILIÇ D, Kaygusuz S, Agalar C (2008). Antimicrobial susceptibility of Brucella melitensis isolates from blood samples. , 257 - 262.
Chicago AYAŞLIOĞLU AÇIKGÖZ ERGİN,KILIÇ SELÇUK,AYDIN Kemalettin,KILIÇ Dilek,Kaygusuz Sedat,Agalar Canan Antimicrobial susceptibility of Brucella melitensis isolates from blood samples. (2008): 257 - 262.
MLA AYAŞLIOĞLU AÇIKGÖZ ERGİN,KILIÇ SELÇUK,AYDIN Kemalettin,KILIÇ Dilek,Kaygusuz Sedat,Agalar Canan Antimicrobial susceptibility of Brucella melitensis isolates from blood samples. , 2008, ss.257 - 262.
AMA AYAŞLIOĞLU AÇIKGÖZ E,KILIÇ S,AYDIN K,KILIÇ D,Kaygusuz S,Agalar C Antimicrobial susceptibility of Brucella melitensis isolates from blood samples. . 2008; 257 - 262.
Vancouver AYAŞLIOĞLU AÇIKGÖZ E,KILIÇ S,AYDIN K,KILIÇ D,Kaygusuz S,Agalar C Antimicrobial susceptibility of Brucella melitensis isolates from blood samples. . 2008; 257 - 262.
IEEE AYAŞLIOĞLU AÇIKGÖZ E,KILIÇ S,AYDIN K,KILIÇ D,Kaygusuz S,Agalar C "Antimicrobial susceptibility of Brucella melitensis isolates from blood samples." , ss.257 - 262, 2008.
ISNAD AYAŞLIOĞLU AÇIKGÖZ, ERGİN vd. "Antimicrobial susceptibility of Brucella melitensis isolates from blood samples". (2008), 257-262.
APA AYAŞLIOĞLU AÇIKGÖZ E, KILIÇ S, AYDIN K, KILIÇ D, Kaygusuz S, Agalar C (2008). Antimicrobial susceptibility of Brucella melitensis isolates from blood samples. Turkish Journal of Medical Sciences, 38(3), 257 - 262.
Chicago AYAŞLIOĞLU AÇIKGÖZ ERGİN,KILIÇ SELÇUK,AYDIN Kemalettin,KILIÇ Dilek,Kaygusuz Sedat,Agalar Canan Antimicrobial susceptibility of Brucella melitensis isolates from blood samples. Turkish Journal of Medical Sciences 38, no.3 (2008): 257 - 262.
MLA AYAŞLIOĞLU AÇIKGÖZ ERGİN,KILIÇ SELÇUK,AYDIN Kemalettin,KILIÇ Dilek,Kaygusuz Sedat,Agalar Canan Antimicrobial susceptibility of Brucella melitensis isolates from blood samples. Turkish Journal of Medical Sciences, vol.38, no.3, 2008, ss.257 - 262.
AMA AYAŞLIOĞLU AÇIKGÖZ E,KILIÇ S,AYDIN K,KILIÇ D,Kaygusuz S,Agalar C Antimicrobial susceptibility of Brucella melitensis isolates from blood samples. Turkish Journal of Medical Sciences. 2008; 38(3): 257 - 262.
Vancouver AYAŞLIOĞLU AÇIKGÖZ E,KILIÇ S,AYDIN K,KILIÇ D,Kaygusuz S,Agalar C Antimicrobial susceptibility of Brucella melitensis isolates from blood samples. Turkish Journal of Medical Sciences. 2008; 38(3): 257 - 262.
IEEE AYAŞLIOĞLU AÇIKGÖZ E,KILIÇ S,AYDIN K,KILIÇ D,Kaygusuz S,Agalar C "Antimicrobial susceptibility of Brucella melitensis isolates from blood samples." Turkish Journal of Medical Sciences, 38, ss.257 - 262, 2008.
ISNAD AYAŞLIOĞLU AÇIKGÖZ, ERGİN vd. "Antimicrobial susceptibility of Brucella melitensis isolates from blood samples". Turkish Journal of Medical Sciences 38/3 (2008), 257-262.